In January 2017, Alexion Pharmaceuticals, Amicus Therapeutics and Sanofi Genzyme joined the Rare Disease Action Forum (RDAF). With this growth, the Forum now includes eight member companies that are all important contributors in the field of rare diseases. Using a multi-stakeholder approach, the RDAF aims at developing and implementing solutions to improve access to diagnosis and treatment for patients with rare diseases in Switzerland. Press release (PDF): English, German, French, Italian
Internationaler Tag der Seltenen Krankheiten 2026: Gemeinsam Fortschritte stärken und die Versorgung nachhaltig verbessern
Am heutigen Internationalen Tag der Seltenen Krankheiten erinnert das Rare Disease Action Forum (RDAF) daran, dass über 500'000 Menschen in der Schweiz von einer seltenen Erkrankung betroffen sind, viele von ihnen weiterhin ohne gesicherten Zugang zu Diagnose,...